| Oct 31 |
Organon declares $0.28 dividend
|
| Oct 31 |
Organon in charts: Revenue from Europe and Canada rises most among geographies in Q3
|
| Oct 31 |
Organon Non-GAAP EPS of $0.87 misses by $0.03, revenue of $1.58B beats by $20M
|
| Oct 31 |
Organon Reports Results for the Third Quarter Ended September 30, 2024
|
| Oct 30 |
Organon Q3 2024 Earnings Preview: Dermavant purchase in focus
|
| Oct 30 |
FDA accepts Organon BLA for Prolia/Xgeva biosimilar
|
| Oct 30 |
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
|
| Oct 28 |
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
|
| Oct 25 |
Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
| Oct 23 |
Organon & Co trades in the red for seven straight sessions
|
